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1. Introduction 
Soft tissue sarcomas (STS) are a heterogeneous group of tumors (Table 1) that account for 
approximately 1% of all adult cancer (Clark et al., 2005). There are more than 50 subtypes that 
are stratified by their histological appearance, presence or absence of characteristic gene 
translocations, or sensitivity to chemotherapy. They can be found in nearly any site in the 
body, but upper and lower extremity soft tissue sarcomas make up approximately 60% of all 
cases (Zagars et al., 2003). Soft tissue sarcomas of the trunk make up another 10% with 
retroperitoneal tumors comprising approximately 15% (Stoeckle et al., 2001). Gastrointestinal 
stromal tumors are the most common mesenchymal tumor of the gastrointestinal tract 
(Miettinen M & Lasota, J 2006). They can occur anywhere along the gastrointestinal tract but 
are most commonly found in the stomach (60%) or small intestine (30%). Other sites are quite 
rare including rectum (3%), colon (1-2%), and esophagus (<1%).  
 
Histology Subtype 
Malignant fibrous histiocytoma  
Liposarcoma 
Well-differentiated, myxoid, round cell, 
pleomorphic 
Leiomyosarcoma  
Synovial Monophasic, biphasic 
Fibrosarcoma  
Rhabdomyosarcoma Embryonal, alveolar, pleomorphic 
Malignant peripheral nerve sheath 
tumor 
 
Angiosarcoma Hemangiopericytoma, lymphangiosarcoma 
Undifferentiated/ unclassified  
Rare/ miscellaneous 
Alveolar soft parts, clear cell, epithelioid, malignant 
mesenchymal, malignant granular cell, mixed 
mesodermal, endometrial stromal 
Table 1. Common Histologies and Subtypes of Soft Tissue Sarcoma 
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The incidence rate for soft tissue sarcoma is approximately 6/ 100000/ year (Ferrari et al., 
2011). Soft tissue sarcomas make up a small fraction of the overall cancer burden. However, 
it occurs in all ages including young adults so there is a disproportionately high economic 
impact in a working population. Approximately 3300 to 6000 gastrointestinal stromal 
tumors are diagnosed annually in the United States with an estimated incidence of 0.68/ 
100000/ year (Tran et al., 2005). The true incidence may be higher depending on the 
proportion of gastrointestinal tumors being tested for c-kit or platelet-derived growth factor 
receptor alpha (PDGFRA). 
The heterogeneity of these tumors presents a challenge in the diagnosis and treatment of 
soft tissue sarcomas and their relative infrequency limits the ability to conduct meaningful 
clinical trials. This chapter will focus on neoadjuvant chemotherapy for adult soft tissue 
sarcomas primarily of the extremity and trunk. Separate sections on retroperitoneal 
sarcomas and gastrointestinal stromal tumors (GIST) will focus on their unique biology and 
potential neoadjuvant treatment strategies. 
2. Initial assessment 
All patients with a suspected soft tissue sarcoma are assessed with a full history 
concentrating on presenting symptoms such as mass, pain, and neurovascular deficits as 
well as constitutional symptoms. For suspected STS of the retroperitoneum or for primary 
GIST, attention is directed to complaints associated with an abdominal mass, early satiety, 
back pain and the development of lymphedema or leg discomfort as well as symptoms of 
gastrointestinal hemorrhage and bowel or urinary obstruction. Physical examination 
includes the chest to rule out obvious findings of metastatic disease such as pleural effusion, 
abdomen for organomegaly or mass, and evaluation of the involved extremity and draining 
lymph node basins. For the extremity, assessment of tumor size, determination of whether a 
mass is mobile and superficial versus fixed and deep to muscular fascia, and an appropriate 
neurovascular assessment including documentation of limb function is required.  
Initial imaging includes plain radiographs of the affected area, chest x-ray and cross-
sectional imaging of the mass with either computer tomography (CT) scan or magnetic 
resonance imaging (MRI). MRI usually gives the most information regarding invasion of 
important neurovascular structures in STS of the extremity or trunk (Heslin & Smith, 1999). 
CT is often quite comparable and can assess potential periosteal or bony invasion, although 
uncommon. CT scan of the chest, abdomen and pelvis is appropriate for the initial 
evaluation of retroperitoneal tumors and GISTs. 
Image or surgeon directed core biopsy obtaining multiple samples generally makes the 
diagnosis of STS in >90% of cases (Hoeber et al., 2001; Welker et al., 2000). In cases where 
core biopsy is non-diagnostic, an incisional biopsy is needed and should be performed by an 
experienced soft tissue oncology surgeon. The incision is made longitudinally on the limb 
directly over the palpable mass so the biopsy tract or incision can be removed at the time of 
definitive surgery. Small (3 cm), superficial soft tissue masses can be removed by excisional 
biopsy, again using a longitudinal incision with minimal skin flaps, careful hemostasis, and 
a complete yet minimal margin. GISTs are usually biopsied via an endoscopic approach 
when in the stomach, duodenum or rectum; or by percutaneous approach or surgery if 
inaccessible via endoscopy. Retroperitoneal sarcomas are more commonly being diagnosed 
with image directed core biopsy, especially in centers where a neoadjuvant approach to 
treatment is considered.  
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Pathologic assessment is performed by a pathologist experienced in the diagnosis and 
grading of STS including microscopic evaluation, immunohistochemistry, and cytogenetic 
and molecular pathologic evaluation as appropriate (Coindre et al., 1988). This may include 
fluorescent in situ hybridization (FISH) or RT-PCR assessing for recurrent chromosomal 
translocations which may be present in up to one third of sarcomas. For GIST, c-Kit (CD117 
(KIT)) immunohistochemistry staining is positive in 95% of cases (Fletcher et al., 2002). 
Analysis for known mutations of KIT and PDGF genes may be used in morphologically 
typical GIST that are CD117 negative. Mitotic count is prognostic and should be expressed 
as the number of mitoses per 50 high-power fields. Further, mutational analysis has 
predictive value for sensitivity to molecular targeted therapy. 
Staging recommendations include CT chest for extremity or trunk STS and CT chest, 
abdomen, and pelvis for retroperitoneal sarcoma and GIST subtypes. CT abdomen and 
pelvis is also employed for some subtypes of STS including myxoid liposarcoma which has 
a more variable metastatic pattern. Sentinel lymph node biopsy is considered in uncommon 
histological subtypes of extremity soft tissue sarcoma including clear cell, epitheliod, or 
angiosarcoma where lymph node metastases are more common (Maduekwe et al., 2009). 
3. Local treatment 
3.1 Local treatment for soft tissue sarcoma of the extremity or trunk 
Level I evidence confirms equivalent outcomes with limb-sparing surgery and adjuvant 
irradiation compared to amputation or wide excision alone (Pisters et al., 1994; Rosenberg et 
al., 1982; Yang et al., 1998). The ideal specific combinations of surgery, radiotherapy and 
possible chemotherapy remain controversial. Multidisciplinary discussions and planning is 
vital; final treatment recommendations often depend more on location of the tumor and 
local expertise than overall evidence. 
Most centers follow treatment protocols using either pre-operative or post-operative 
irradiation and limb-sparing, function-preserving surgery for STS. The optimum timing of 
radiation therapy was evaluated in a randomized control trial that showed no overall 
differences in local control, disease-free survival or overall survival between treatment 
arms (O’Sullivan et al., 2002). Wound complications were higher (35% v 17%; p=0.01) in 
the group treated with pre-operative radiation, and were most significant in the lower 
limb. Those treated with postoperative radiation had better function at 6 weeks post 
surgery but no significant differences at later time points (Davis et al., 2002). However, 
there was more late radiation morbidity from fibrosis in the postoperative radiation arm. 
Significant fibrosis was associated with more joint stiffness and edema adversely affecting 
patient function (Davis et al., 2005).  
Soft tissue sarcomas superficial to muscular fascia or atypical lipomas/ well-differentiated 
liposarcomas are more often treated with limb-sparing surgery alone with clear microscopic 
margins (Kooby et al., 2004; Pisters et al., 2007). However, combination of limb sparing 
surgery and irradiation in some fashion is the standard of care for the majority of soft tissue 
sarcomas of the extremity or trunk.  
3.2 Identification of high-risk soft tissue sarcoma 
Important factors predictive of a higher local recurrence for STS include positive margins 
following resection, presentation with locally recurrent disease, and high grade pathology 
(Eilber et al., 2003; Pisters et al., 1996). Prognostic factors predictive of systemic recurrence 
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and death include older age at diagnosis (> 60 years), increasing tumor size (>5, 5 to 10, or > 
10 cm), higher tumor grade, depth (deep to muscular fascia) and site (head and neck, 
abdominal, retroperitoneal and trunk worse than extremity) (Coindre et al., 2001; Kattan et 
al., 2002; Pisters et al., 1996). In a large series of 1225 patients treated with limb-sparing 
surgery and radiation for localized STS, the risk of local or distant relapse was highest in the 
first few years, with approximately two thirds of recurrences by 2 years and more than 90% 
by 5 years (Zagars et al., 2003). Unfortunately, approximately 50% of those with high risk 
STS die of their disease. Hence, it is in these high risk sub-groups that the role of 
chemotherapy is usually explored.  
4. Effective chemotherapeutic agents 
Doxorubicin is the most active agent in metastatic STS excluding GISTs with response rates 
from 20-30%(Edmonson et al., 1993; Eriksson 2010). Ifosfamide is the second most 
commonly used agent with response rates of 15-30%. Combination chemotherapy of 
doxorubicin and ifosfamide or cyclofosfamide appears to have an increased tumor response 
in the metastatic setting but the toxicity is similarly increased (Eriksson 2010). A randomized 
trial is currently enrolling comparing doxorubicin alone versus doxorubicin plus ifosfamide 
in the metastatic setting (Verschraegen et al., 2010). At present, either doxorubicin or 
ifosfamide or the combination is considered first line for metastatic soft tissue sarcoma. 
Similarly, doxorubicin or ifosfamide or the combination is the most common agents used in 
the adjuvant setting. 
Other potential agents for treatment of soft tissue sarcomas in the metastatic setting include 
dacarbazine or its oral analogue temozolomide (often in the multidrug combination of 
MAID – mesna, doxorubicin, ifosfamide and dacarbazine), gemcitabine, taxanes such as 
paclitaxel, the combination of gemcitabine and docetaxel, vinca alkaloids such as 
vinorelbine, trabectedin , as well as etoposide. Although these agents have been used as 
second or third line in the metastatic setting, use in the adjuvant setting is uncommon.  
4.1 Adjuvant chemotherapy for soft tissue sarcoma of the extremity and trunk 
The use of adjuvant chemotherapy in soft tissue sarcoma is controversial. Some randomized 
trials have suggested chemotherapy improves disease-free and overall survival while many 
have not (Frustaci et al. 2001). Issues with the study of adjuvant chemotherapy in STS 
include the lack of a highly effective agent, the heterogeneity of tumors within the grouping 
STS, the rareness of the disease, and the potential dilution of effect in clinical trials by 
inclusion of all patients regardless of risk, including those unlikely to benefit.  
The largest meta-analysis of doxorubicin-based chemotherapy assessed individual patient 
data from 14 trials and did show an improvement in disease-free survival but no 
improvement in overall survival (Tierney et al., 1997). However, subset analysis notes an 
absolute 7% improvement in disease-free survival and an absolute 4% improvement in 
overall survival for the subgroup of patients with STS of the trunk or extremity with tumors 
greater than 5 cm and high grade (grades 2 or 3 out of 3). Other subtypes of STS by location, 
size, or grade showed no differences in disease-free or local survival. The same meta-
analysis notes insufficient evidence to make recommendations for adjuvant chemotherapy 
for retroperitoneal sarcomas. Further, it was felt there are insufficient data to determine 
whether single-agent doxorubicin or combination chemotherapy should be recommended. 
An updated meta-analysis with four additional trials including the use of ifosfamide in the 
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adjuvant studies found the hazard ratios of local, distant and overall survival were 0.73 
(95% CI 0.56-0.95), 0.65 (95% CI 0.53-0.80), and 0.67 (95% CI 0.56-0.82) respectively in favor 
of adjuvant chemotherapy (Pervaiz et al., 2008). 
5. Neoadjuvant therapies for soft tissue sarcoma of the extremity and trunk 
Early administration of chemotherapy in STS can theoretically treat micro-metastatic 
disease, decrease the rate of distant metastatic disease and improve overall survival. Early 
non-randomized trials suggest a higher response rate for primary tumors compared to 
chemotherapy given in the setting of distant metastases (Rouessse et al., 1987). Therefore, 
preoperative chemotherapy may have a role in downstaging primary tumors to improve 
resectability. Finally, response to chemotherapy in vivo could affect choices of postoperative 
adjuvant chemotherapy. 
5.1 Neoadjuvant systemic chemotherapy 
One randomized trial has assessed neoadjuvant systemic chemotherapy for STS. The small 
(134 patients) multicenter trial by Gortzak et al. (2001) assessed preoperative chemotherapy 
with doxorubicin and ifosfamide vs. no preoperative therapy in patients aged 15-75 with 
high risk STS. High risk was defined as tumors  8 cm of any grade, or grade II/III tumors < 
8 cm, or grade II/III locally recurrent tumors or grade II/III tumors with inadequate surgery 
performed in the previous 6 weeks which required further surgery. Preoperative 
chemotherapy consisted of three cycles of doxorubicin (q 3 weeks -50mg/m2 bolus) and 
ifosfamide (5 g/m2) by 24-hour infusion. Surgery occurred within 3 weeks of completion of 
chemotherapy. Surgery was planned at randomization in both arms and could include 
amputation, compartmental resection, wide or marginal excision. Postoperative radiation 
could be used if marginal surgery, for microscopically positive margins with no possibility 
of further surgery with limb salvage, or in cases of surgery for local recurrence. Although 
150 were initially entered into the trial, 134 were eligible with randomization of 67 to each 
arm. The response rate was 28% in the chemotherapy arm (8% complete, 20% partial); no 
different than the usual response in the setting of metastatic disease. Side effects from 
chemotherapy arm included alopecia, nausea and emesis (95%), and leukocytopenia (32%). 
There was an 8% grade IV leukocytopenia rate and one grade V complication (death) from 
febrile neutropenia. Surgical outcomes included 88% limb salvage and 12% amputation rate. 
At median follow-up of 7.3 years, 5-year disease-free survival was 52% and 56% in the 
surgery alone and chemotherapy arms respectively (p=0.35). Overall 5-year survival was 64 
and 65% respectively (p=0.22). A priori sample size calculations estimated 269 patients were 
required to detect a 15% increase in 5-year survival. Although closed prior to its planned 
accrual, it was felt the study results made it unlikely that a major survival benefit would be 
achieved with preoperative systemic doxorubicin and ifosfamide. The authors note 
preoperative chemotherapy was feasible and did not compromise subsequent surgery, 
radiation treatments or wound healing.  
A retrospective analysis by Meric et al. (2000) had similar findings with regards to surgical 
complications. They compared 204 patients having surgery first to 105 who had 
preoperative chemotherapy with various regimes including combinations or single agent 
doxorubicin, ifosfamide, dacarbazine, cyclophosphamide, or mesna. Generally, those in the 
neoadjuvant chemotherapy group had large tumors (12 vs. 8 cm), a higher proportion of 
high grade tumors (90 vs. 64%) and were younger (age 47 vs. 55 years of age). The incidence 
www.intechopen.com
 
Neoadjuvant Chemotherapy – Current Applications in Clinical Practice 
 
198 
of surgical complications was similar (34 vs. 41% for extremity; 29 vs 34% for 
retroperitoneal/ visceral) with the majority of complications being wound infections or 
other wound complications. The main predictors of wound complications were preoperative 
radiation, autologous flap coverage, and those with lower extremity tumors, rather than the 
use of neoadjuvant chemotherapy.  
A two center retrospective analysis by Grobmyer et al. ((2004) assessed preoperative 
systemic chemotherapy with doxorubicin, ifosfamide and mesna followed by surgery (74 
patients) versus surgery alone (282 patients) for the time period 1990-2001. Inclusion 
criteria included high-grade, deep, >5cm extremity soft tissue sarcomas. Overall, there 
was a younger median age in the group treated with neoadjuvant chemotherapy (50 years 
vs. 62 years) and more of the synovial sarcoma histological subtype. Size was similar but 
slightly larger in the neoadjuvant group (median 12 cm vs. 10 cm). With potential 
imbalances that may favor the surgery alone arm, the unadjusted hazard ratio for the 
effect of neoadjuvant chemotherapy on disease-specific survival was 0.75 (95% CI:0.45-
1.2). Following multivariate analysis including factors size, histology and age, the HR for 
the effect of neoadjuvant chemotherapy on disease-specific survival was 0.52 (95%CI:0.30-
0.92). Three year disease-specific survival for tumors greater than 10 cm was 83 %(72-95) 
vs. 62% (53-71) for those treated with neoadjuvant chemotherapy vs. surgery alone 
respectively. The authors felt the study suggests an association between neoadjuvant 
chemotherapy and disease-specific survival but caution the retrospective nature of the 
study had distinct limitations. 
At present, there is no convincing evidence for the routine use of systemic dose 
neoadjuvant chemotherapy alone in the treatment of soft tissue sarcoma of the extremity. 
However, neoadjuvant protocols continue to be developed. The overall challenge with 
neoadjuvant systemic chemotherapy has been the lack of a highly effective agent. 
5.2 Neoadjuvant chemoradiation 
A number of primarily single center trials assess the approach of neoadjuvant 
chemoradiation in the treatment of STS. Advantages of combining chemotherapy and 
radiation include the potential of using a lower dose of radiation and possibly avoiding side 
effects such as wound complications associated with high dose preoperative radiation. 
Downstaging can occur and resection margins may be less radical, especially near critical 
neurovascular structures. Although the literature often suggests neoadjuvant chemotherapy 
given with radiation may still theoretically treat micro-metastatic disease, it is important to 
recognize that the chemotherapy dose is often significantly reduced, in which case it is being 
used primarily as a radiosensitizer. Generally trials can be divided into those with 
neoadjuvant chemoradiation usually with chemotherapy as a radiosensitizer versus trials 
with systemic neoadjuvant chemotherapy with radiation interdigitated between cycles. 
Based on a prior pilot study, an important phase II trial by the Radiation Therapy Oncology 
Group assessed systemic dose preoperative chemotherapy interdigitated with preoperative 
radiation therapy followed by 3 cycles of postoperative chemotherapy (Delaney et al., 1996; 
Kraybill et al., 2006). Sixty-six patients were enrolled with 64 analyzed. Preoperative 
chemotherapy consisted of 3 cycles of mesna, doxorubicin, ifosfamide and dacarbazine 
(MAID) with 44 Gy of preoperative radiation; twenty-two Gy was given in 11 daily fractions 
between cycle 1 and 2 as well as cycle 2 and 3. Seventy-nine percent completed preoperative 
chemotherapy and 59% completed all chemotherapy. Three patients died from grade 5 
toxicity (hematologic/ infectious) and 83% had grade 4 toxicities with the majority being 
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hematologic. There was a 22% partial response rate based on radiology and 27% had no 
viable tumor at pathologic review. Sixty-one patients came to surgery with 58 R0 resections 
including 5 amputations. The 3-year rate of local regional failure was 10.1%. Three year 
disease-free, distant disease-free, and overall survival was 56.6%, 64.5%, and 75.1% 
respectively. The three-year survival rates were promising compared to the literature 
dealing primarily with large, high grade tumors. The trial authors conclude that an 
aggressive neoadjuvant regime can be delivered in a cancer cooperative group. However, 
the substantial toxicity of the treatment precludes its use outside of clinical trials. It is 
suggested the future of this regime may be a modified version with possible targeted 
therapies and reduced doses of cytotoxic agents.  
The most recent publication of neoadjuvant chemoradiation where full dose chemotherapy 
is used involves 25 patients with intermediate or high-grade soft tissue sarcomas with 3 
cycles of pre and postoperative epirubicin and ifosfamide with 28 Gy of irradiation given in 
8 fractions during cycle 2 of chemotherapy (Ryan et al., 2008). Sixteen patients completed the 
entire treatment but 21 had grade 4 toxicity which was generally hematologic such as febrile 
neutropenia and anemias. Postoperative wound complications occurred in 20%. Forty 
percent of resected specimens showed >95% pathologic necrosis. The 2-year overall and 
disease-free survival rates were 84 and 62%. Although the high pathologic response rate was 
encouraging, the relatively high rate of major toxicity limited the use of this protocol.  
Overall, full dose systemic chemotherapy with interdigitated radiation has not been 
successful in convincingly improving disease-free or overall survival for patients with high-
risk tumors. Although higher response rates have been reported, these generally have 
trended with higher toxicity.  
A phase I trial of concurrent preoperative doxorubicin and radiation used full-dose 
radiation (50Gy) with varying doses of 4-day continuous doxorubicin (Pisters et al., 2004). 
This is the only reported trial of truly concurrent chemoradiation. The maximum tolerated 
dose of continuous-infusion doxorubicin was 17.5mg/m2/week. Among 22 patients 
treated with this dose and full-dose radiation, 50% had a greater than 90% tumor necrosis 
rate including 2 patients with a complete pathologic response. Six patients (23%) 
experienced major wound complications requiring hospital admission; two patients 
required re-operation. 
An early neoadjuvant chemoradiation regime where chemotherapy was used as a 
radiosensitizer was developed and popularized by Eilber et al. (2003) at the University of 
Calfornia, Los Angeles (UCLA). An initial protocol combined intra-arterial doxorubicin 
and sequential hypofractionated radiation (35 Gy in 3.5 Gy fractions) followed by limb-
sparing surgery. In a small series, all patients avoided amputation and the local 
recurrence rate was 3%; the best local control rate in the literature. However, 
postoperative wound complications were considerable with 23% of patients requiring re-
operation. Following further experimentation of the protocol, the most widely published 
regime included 28 Gy in 3.5 daily fractions. Further, intra-arterial chemotherapy was 
changed to being given intravenously. Eilber et al. (2001) noted that a pathologic complete 
response following neoadjuvant chemoradiation was associated with improved local 
recurrence as well as overall survival. 
Further modification of the Eilber protocol occurred at the University of Calgary (Mack et 
al., 2005). This protocol uses 3 consecutive days of systemic doxorubicin with sequential 10 
fractions of 3 Gy preoperative irradiation; total dose 30 Gy. The largest report of this 
protocol assessed 75 consecutive patients with a 3% 5 year local recurrence rate and a 63% 5 
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year overall survival. The major wound complication rate of 4% was much lower than other 
preoperative full-dose radiation protocols. Although local recurrence rates are quite 
favorable, overall survival data appears unchanged compared to the literature. Wanebo et 
al. (1995) also reported on 66 patients treated with preoperative doxorubicin and 3-4600 cGY 
of radiation. In this tricentre study, the 5-year local recurrence rate was 2% and 5 year 
overall survival was 59%. Other series have been published using various modifications of 
the Eilber protocol or neoadjuvant chemoradiation strategies with similarly low local 
recurrence rates (Goodnight et al., 1985; Levine et al., 1993; Pisters et al., 2002). 
Therefore, the role of using chemotherapy as a radiosensitizer has promise in terms of local 
control but not in terms of distant disease control or overall survival. Thus far, this approach 
has been explored primarily in single centers and has not been studied in a comparative trial.  
5.3 Neoadjuvant chemotherapy and regional hyperthermia 
Another modification of neoadjuvant chemotherapy is the combination of chemotherapy or 
radiation with hyperthermia; the tumor is heated to improve the effects of the 
chemotherapy or radiation. The theory of using hyperthermia is that heat kills cells via 
thermal toxicity, increases drug efficacy, and induces a tumoricidal immune response. 
In a phase III trial of 341 patients with large, high-grade sarcomas (extremity or trunk), 
patients were randomized to neoadjuvant etoposide, ifosfamide and doxorubicin plus or 
minus concurrent hyperthermia (Issels et al., 2010). Treatment response was 12.7% in the 
neoadjuvant chemotherapy arm and 28.8% in the neoadjuvant chemotherapy with 
hyperthermia arm. The majority of patients (90%) went on to surgery with 6.7% and 8.9% 
having an amputation in the combination arm and chemotherapy arm respectively. 
However, only about two thirds had a definitive surgical resection with approximately one 
third not having a definitive surgery as felt to be impossible. The reasons for unresectability 
were not explicitly described. The R0 resection rate was quite low at 51% and 41.6% in the 
combination and chemotherapy alone arms respectively. Approximately two thirds of 
patients had adjuvant radiation. Local control was improved in the hyperthermia arm (HR 
0.58, 95% Cl 0.41-0.83;p=0.003) compared to the chemotherapy alone group. Further, overall 
survival was better in the combined arm (HR 0.66; 95% CI 0.45-0.98, p=0.038).  
Although there have been other phase II trials of this combination treatment, few centers 
have adopted the approach (Schlemmer et al., 2010). At present, the potential benefits of this 
new intervention are restricted to patients with very high-risk soft tissue sarcomas in the 
context of a clinical trial. 
5.4 Isolated limb infusion or perfusion 
Isolated limb perfusion (ILP) uses high-dose regional chemotherapy where the blood supply 
to the limb is isolated from the rest of the body by an extracorporeal circulation. It involves a 
complex and invasive technique by clamping and cannulating the major artery and vein 
after heparinization of the patient, connection to an oxygenated high-flow extracorporeal 
circuit, ligation of collateral vessels, and the application of a tourniquet at the root of the 
limb to occlude superficial veins (Hoekstra 2008). Isolated limb infusion (ILI) is a modified, 
more minimally invasive technique via percutaneously placed catheters (Kroom & 
Thompson 2009). Further, ILI is low flow and performed under hypoxic conditions. The 
intent is still to provide regional chemotherapy but without the potential morbidity of a 
surgical procedure.  
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Most commonly, agents used for soft tissue sarcoma of the extremity include tumor necrosis 
factor-alpha (TNF-), melphalan, doxorubicin, cisplatin, carboplatin and actinomycin-D 
(Hoekstra 2008; Kroon & Thompson 2009). TNF- is only available in Europe. The use of 
either procedure is limited to large soft tissue tumors initially felt to be unresectable without 
amputation. It is sometimes used in a palliative fashion in those with large unresectable and 
symptomatic tumors in the setting of small volume metastatic disease. Although relatively 
toxic to local tissues, it also has quite high response rates and may allow limb salvage in 70-
90% in the short-term and as high as 60% at 5 to 10 years (Di Filippo et al., 2009; Grunhagen 
et al., 2005; Moncrieff et al., 2008). Complete and partial response rates range from 0-70% 
and 0-74% respectively (Hoekstra 2008). A randomized trial found no differences in 
response with varying doses of TNF- but systemic toxicity did correlate with higher drug 
dosage (Bonvalot et al., 2005). 
6. Retroperitoneal sarcoma 
6.1 Local treatment for retroperitoneal sarcomas 
Unlike extremity/ trunk STS where surgery and radiation is accepted as the standard of 
care, the most appropriate treatment of retroperitoneal sarcoma is less clear. En bloc 
resection of the retroperitoneal STS plus adjacent organs to obtain a negative margin is the 
most common treatment (Lewis et al., 1998). Unfortunately, as many as 20-60% of tumors 
are deemed unresectable at presentation or gross residual disease remains after a resection 
attempt (Catton et al., 1994; Lewis et al., 1998; Sindelar et al., 1993) In this group, there is no 
survival benefit to partial or incomplete gross resection (Lewis et al., 1998). Even when 
completely resected, about 25% of cases have microscopically positive margins; potentially 
higher depending on the intensity of the pathologic evaluation. In a large series, 19% and 
41% local recurrence rates at 2 and 5 years respectively were described for those having a 
complete resection (Lewis et al., 1998). Local recurrence without the development of 
systemic disease is the leading cause of death in retroperitoneal sarcomas.  
Some centers are commonly using preoperative irradiation in an effort to improve upon 
local control and possibly overall survival for retroperitoneal sarcoma. Theoretical 
advantages of preoperative irradiation include the gross tumor volume is more clearly 
demarcated since still in situ, radiosensitive viscera are displaced by the tumor outside of 
the radiation field, the biologically effective dose is lower preoperatively as the tumor is 
still well oxygenated, a higher dose can be delivered to the tumor since there are fewer 
surgical adhesions (less scar), and the tumor is treated preoperatively prior to potential 
contamination by surgery (Raut & Pisters 2006). Two prospective protocols from the MD 
Anderson Cancer Center and the University of Toronto employed pre-operative 
irradiation (45-50 Gy) followed by surgery (Pawlik et al., 2006). At median follow-up of 40 
months, combined results showed 5-year local recurrence free, disease free and overall 
survival rates of 60%, 46%, and 61% respectively. Using 45 Gy of pre-operative irradiation 
but with the use of surgically placed intra-abdominal spacers to displace small intestine 
and allow maximal irradiation to the tumor margin, White et al. (2007) describe an 80% 5 
year local control rate in a series of 23 patients.  
Unfortunately, a phase III trial randomizing between preoperative external beam 
irradiation (45-50.4 Gy) and surgery versus surgery alone was closed due to poor accrual 
(Raut & Pisters 2006). 
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6.2 Neoadjuvant chemotherapy and chemoradiation 
The high local recurrence rate after surgery alone has led to combined modality 
approaches to potentially improve local control. As noted, preoperative irradiation 
protocols are the most commonly explored. However, there have also been a few attempts 
of neoadjuvant chemotherapy or neoadjuvant chemoradiation protocols. A study of 16 
patients with 3 to 5 cycles of preoperative chemotherapy alternating with irradiation 
therapy led to 11 surgical resections and 4 R0 resections in advanced, large (median  
17 cm) retroperitoneal sarcomas (Robertson et al., 1995). Two further studies of concurrent 
chemoradiation noted feasible complication rates (11% admission rate for toxicity) and a 
fairly high (26%) complete pathologic response rate (Eilber et al., 1995; Pisters et al., 2003). 
Finally, a retrospective review of 55 patients having neoadjuvant chemotherapy (plus 
preoperative radiation in 56%) found no difference in disease-specific or overall survival 
compared to predicted outcomes (Donahue et al. 2010). However, those with a greater 
than 95% pathologic necrosis (25% of cohort) had much improved disease-specific 
survival compared to non-responders. 
A phase II trial of preoperative combined modality treatment for intermediate or high-
grade retroperitoneal sarcoma with doxorubicin and ifosfamide followed by preoperative 
irradiation followed by surgery and an intraoperative or postoperative boost was closed 
due to poor accrual (Raut & Pisters 2006). Concerns regarding the rare incidence of this 
tumor subtype and institution specific protocols were the most likely reasons for 
insufficient timely accrual. 
7. Gastrointestinal stromal tumors (GISTs)  
7.1 Local treatment of gastrointestinal stromal tumors 
The mainstay of treatment for GIST is complete surgical excision with negative margins 
without dissection of clinically negative nodes (Dematteo et al., 2002). Adjuvant irradiation 
does not have a role for these intra-abdominal tumors. 
7.2 Role of imatinib  
The prognosis of GISTs is primarily related to mitotic index and tumor size (Table 2) 
(Fletcher et al., 2002). The risk of relapse is based on these factors as well as site, surgical 
margins and whether tumor rupture has occurred (Casali & Blay, 2009). Most patients with 
localized disease and deemed low risk have surgery alone. 
For patients with intermediate or high-risk tumors, adjuvant imatinib is considered. 
Imatinib is a highly active targeted therapy for patients with GIST. The ACOSOG Z9001 
trial compared one year of adjuvant imatinib with placebo in patients with complete 
resection of their primary GIST which was intermediate or high-risk based on size alone 
(Dematteo et al., 2007). Based on 756 patients and an interim analysis, the relapse free 
survival at one year was 97% in the imatinib arm compared to 83% in the placebo arm. 
This was highly significant and the trial was unblinded; those on placebo crossed over to 
one year of adjuvant imatinib. There was no overall survival benefit at this point in the 
trial and this may never be demonstrated due to the crossover of patients after the 
interim analysis. Therefore, the use of adjuvant imatinib in all patients has been 
questioned until an overall survival benefit can be demonstrated. Fortunately, a European 
placebo controlled trial continues and is powered to detect overall survival differences 
(Joensuu et al., 2011).  
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 Size Mitotic Count 
Very low risk < 2 cm <5/ 50 high power fields (HPF)
Low risk 2-5 cm <5/ 50 HPF 
Intermediate risk
< 5 cm 
5-10 cm 
6-10/ 50 HPF 
<5/ 50 HPF 
High risk 
>5 cm 
>10 cm 
Any size
>5/ 50 HPF 
Any mitotic count 
>10/ 50 HPF 
Table 2. Approach for Defining Risk of Aggressive Behavior in GISTs.  
Finally, those patients presenting with locally advanced inoperable tumors or with 
metastatic disease, palliative intent chemotherapy with imatinib is the standard of care 
(Blanke et al., 2008). Objective response rates of 50-60% occur with only 10-15% of tumors 
having primary progression. The first-line dose is 400 mg per day; however, those with exon 
9 KIT mutations appear to do better with 800 mg daily (Verweij et al., 2004). Further, in 
cases of tumor progression, imatinib is increased to 800 mg daily. Second-line therapy 
includes sunitinib and other anti-tyrosine kinase agents or clinical trial (Casali & Blay, 2010). 
Gastrointestinal stromal tumors are considered refractory to conventional, systemic 
chemotherapy (Trent et al., 2003). 
7.3 Neoadjuvant imatinib in gastrointestinal stromal tumors (GISTs) 
Since GISTs have a high response (50-60%) to imantinib in the metastatic setting, 
neoadjuvant strategies have been explored to attempt to reduce the surgical procedure 
required or downstage (Blanke et al., 2008 Verweij et al., 2004). Currently, ESMO guidelines 
recommend neoadjuvant imantinib in patients for whom a complete R0 resection is not 
feasible and for patients who are candidates for less mutilating surgery (Casali & Blay, 
2009). Similarly, NCCN guidelines recommend neoadjuvant imatinib for marginally 
resectable tumors or resectable tumors with risk of significant morbidity. Finally, Canadian 
guidelines consider neoadjuvant imatinib if surgery may result in significant morbidity of 
loss of organ function (Blackstein et al., 2006). Generally, in these scenarios, subsequent 
surgery is considered 4-12 months later after maximal tumor response (Figure 1).  
A phase II trial of neoadjuvant imatinib was reported by Eisenberg et al. (2009) for advanced 
primary (30 patients) and metastatic/recurrent yet operable (22 patients) gastrointestinal 
stromal tumors. Imatinib was used for 8-12 weeks prior to surgery at 600 mg per day. 
Generally, imatinib was tolerated with 21% grade 3 complications, 12% grade 4 and 2% 
grade five complications. The response rates by RECIST criteria for primary tumors is 
partial (7%), stable (83%), and unknown (10%). For those with metastatic/ recurrent yet 
operable tumors the response was partial (4.5%), stable (91%), and progression (4.5%). 
Postoperative complications were consistent with a surgical patient series with extensive 
and re-operative surgery. The type of surgery performed included a single or partial organ 
resection (53%), multi-organ resection (36%), as well as combinations of organs and 
peritoneal implants (11%). In the advanced primary tumor group, an R0 resection (no 
residual gross or microscopic disease) was possible in 77%, R1 (no residual gross disease but 
microscopic residual) in 15% and R2 (gross disease remaining) in 8%. In the metastatic or 
recurrent yet operable setting, similar rates were 58%, 5%, and 32% respectively for R0, R1, 
and R2 resections. The two-year progression free survival was 80.5% and 82.7% in the two 
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groups,. The 2-year overall survival was 93.3% and 90.9% in the group with advanced 
primary versus metastatic or recurrent yet operable disease, respectively. The overall 
conclusions of this multicenter trial were that neoadjuvant imatinib in the case of locally 
advanced primary or metastatic GIST was feasible, requires multidisciplinary 
considerations, and was not associated with increased postoperative complications.  
 
   
Fig. 1. CT Scans showing Large GIST Before (left) and After (right) Neoadjuvant Imatinib.  
8. Future directions 
The main difficulties with the use of neoadjuvant therapies for soft tissue sarcoma of the 
extremity, trunk or retroperitoneum include issues with the lack of a highly effective agent, 
the heterogeneity of tumors subtypes, the rareness of patients with the disease for 
participation in clinical trials, and the potential dilution of effect in clinical trials by inclusion 
of all patients regardless of risk, including those unlikely to benefit. By contrast, patients 
with gastrointestinal stromal tumors now have a highly effective agent (imatinib) in the 
metastatic setting with the potential of exploring additional neoadjuvant protocols.  
Identification of similar chromosomal translocations and gene microarray technology are 
playing increasing roles in the diagnosis of soft tissue sarcoma and potential identification of 
therapeutic targets (Borden et al., 2003; Nielsen et al., 2006). Dynamic positron emission 
technology (PET) imaging is being used to evaluate treatment responses after initial cycles 
of neoadjuvant chemotherapy (Dimitrakopoulou-Strauss et al., 2010). Further, there does 
appear to be a histopathologic correlation of treatment response and PET imaging which 
may allow early treatment decisions as to continuing or discontinuing neoadjuvant 
chemotherapy (Benz et al., 2009). 
9. Conclusion 
Although limb-sparing, function-preserving surgery plus radiation in some fashion is the 
current standard of care for soft tissue sarcoma of the extremity or trunk, neoadjuvant 
chemotherapy and chemoradiation strategies continue to be explored and employed 
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especially in large, high-risk tumors. At present, the success of these strategies have been 
limited primarily due to the lack of an effective agent in soft tissue sarcoma, especially in 
terms of distant disease free and overall survival rates. The development of new, targeted 
therapies based on the distinct histologic and biologic differences among subtypes of soft 
tissue sarcoma is required. 
The use of a highly effective agent, imatinib as well as other tyrosine kinase inhibitors in the 
treatment of gastrointestinal stromal tumors, either neoadjuvantly, adjuvantly, or in the 
metastatic setting will hopefully correlate with similar development of targeted therapies for 
soft tissue sarcoma. 
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